EN DE
Watch Daxor Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Daxor Corporation (DXR) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Daxor Corporation stock $25.35, price $8.45, upside +200.0%, quality 57 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DC Daxor Corporation logo Thin data Nov 6, 2026

Daxor Corporation

DXR · US
Undervalued, but in a downtrend

The stock costs 67% less than our calculation considers fair.

Fair value $25.35 · Strongly undervalued
Low debt
Ranks above peers (8/9)
Wide moat 65/100
Revenue last quarter +26% vs. a year ago.
Quality 57/100
Mixed Growth
Negative free cash flow
Thin data
Watch Daxor Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.75 $7.05 Fair Value $25.35 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $7.05 – $14.75 · fair‑value band $18.20 – $31.70 · the $8.45 price screens below the $25.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Daxor in your weekly email

Every Wednesday you see whether Daxor is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.

Show moreShow less

The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

Stock analysis

Daxor Corporation (DXR) currently trades at $8.45, while our model-based Fair Value estimate is $25.35, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $26.10 per share, and 9 of the 12 models we run sit above the $8.45 price.

Bear case: the Asset-Based group reads lowest at $5.27, and 3 of the 12 models stay below the price. Data coverage for this calculation is low.

Scenario range: $18.20 (bear) to $31.70 (bull), the price of $8.45 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

Daxor Corporation reported revenue of $503K in FY2025 versus $5.8M in FY2021, a compound −45.8%/yr. Reported net income was $9.2M in FY2025, compounding +17.9%/yr from FY2021.

Key figures

Market cap $52.0M Micro · P/E ratio 7.7 · EPS (TTM) $1.10 · Return on equity 14.2% · Return on assets (EBIT) 11.8% (5-year average) · Operating margin −4,530% · Revenue growth (YoY) +25.5% · EPS growth (YoY) +329%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (medium confidence).

What moves the price

The share trades about 43% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 200%, DXR screens cheaper than that median.

Fair Value models

Bear $18.20 Fair Value $25.35 Bull $31.70
Price $8.45 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.9433 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $11.02 $12.50 $13.73 74
ROIC Compounder $11.02 $12.84 $14.61 72
Residual Income $8.49 $10.12 $12.98 71
All 12 models by family
Earnings-Based
Graham-Dodd $10.68 $13.05 $14.69 67
EPV $11.02 $12.50 $13.73 74
Multiples
P/E Multiple $25.92 $34.55 $43.19 63
P/S Multiple $0.2300 $0.3000 $0.3800 58
P/B Multiple $12.40 $16.54 $20.67 55
EV/EBIT $20.04 $26.73 $33.42 66
EV/EBITDA $19.09 $25.45 $31.82 67
EV/Revenue $0.1600 $0.2400 $0.3200 53
Asset-Based
NCAV (Graham) $3.93 $5.27 $7.86 54
Economic Profit
Residual Income $8.49 $10.12 $12.98 71
ROIC Compounder $11.02 $12.84 $14.61 72
Growth Earnings
Growth-Adj P/E $18.27 $26.10 $33.93 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 54
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 47
Does it invest with discipline instead of growing at any price?
Low Volatility 66
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyMichael Richard FeldschuhChief Executive Officer, Director1,000 shares at $9.07$9,070Apr 8, 2026
  • BuyRobert J MichelChief Financial Officer2× since Dec 9, 2025: 4,000 shares, avg. $2.48$9,900Mar 31, 2026
  • BuyJohn JefferiesChief Medical Officer2× since Nov 12, 2025: 8,285 shares, avg. ?Mar 20, 2026
  • BuyJonathan Adam FeldschuhChief Scientific Officer, Director18,000 shares at ?Dec 9, 2025

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−24.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.9.4% vs 17.1%, slowing
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.82% → 1,825%
2025 sits 1,561% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)

Watch DXR, get fair value alerts →

Compare Daxor Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Below median
Fair Value upside +200.0% · Top 25%
Profitability
Return on equity (12 months) 14.2% · Top 25%
Return on assets 19.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 25.5% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 7.7× · Cheapest 25%
P/B 1.13× · Cheapest 25%
EV/EBITDA 5.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 26
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)57 · sector 30
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs DXR
EssilorLuxottica Société anonyme EL €190.60 €196.22 +3% vs DXR
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs DXR
Medline Inc MDLN $39.64 $28.59 −28% vs DXR
Alcon Inc ALC CHF 61.22 CHF 34.06 −44% vs DXR
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs DXR
Straumann Holding STMN CHF 105.45 CHF 45.50 −57% vs DXR
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs DXR
Sartorius Stedim Biotech S.A DIM €226.20 €54.82 −76% vs DXR
Sartorius Aktiengesellschaft SRT €229.00 €42.50 −81% vs DXR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Daxor Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Daxor Corporation Fair Value". https://www.fairvalue-calculator.com/stock/DXR

Frequently asked questions

Is Daxor Corporation (DXR) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $25.35 versus a price of $8.45, about +200% upside (undervalued).
What is the fair value of DXR?
Our model-based fair value for Daxor Corporation is $25.35 (as of Nov 6, 2026), built from audited fundamentals. The current price: $8.45.
What is the quality score of DXR?
Daxor Corporation has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daxor Corporation (DXR)?
Our model-based price target is the fair value of $25.35 (as of Nov 6, 2026) from 12 valuation models. Cautious scenario $18.20, optimistic scenario $31.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Daxor Corporation stock forecast for 2026?
Our models put fair value at $25.35, about +200% upside versus a price of $8.45 (undervalued). Cautious scenario $18.20, optimistic scenario $31.70. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Daxor Corporation (DXR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daxor Corporation it is $25.35 per share (as of Nov 6, 2026), against a price of $8.45. It is the blended result of 12 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daxor Corporation stock overvalued or undervalued in 2026?
As of Nov 6, 2026, DXR trades below its calculated fair value: price $8.45, fair value $25.35, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DXR?
No. The price is what the market pays today ($8.45); the fair value is what the company's own numbers justify ($25.35). For Daxor Corporation the two are $16.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Daxor Corporation worth?
The market values Daxor Corporation at about $52.0M (market capitalisation, as of Nov 6, 2026). Per share that is $8.45; our models calculate a fair value of $25.35 per share.
What do the bullish and bearish scenarios say about DXR?
Our models span a range for Daxor Corporation: cautious scenario $18.20, base $25.35, optimistic $31.70 per share (as of Nov 6, 2026, price $8.45). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DXR?
Daxor Corporation trades at a price-to-earnings ratio of 7.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $25.35 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2016 to 2025), reported earnings: 18.4. Other multiples: P/B 1.1, EV/EBITDA 5.7.
How solid is the balance sheet of Daxor Corporation (DXR)?
Balance-sheet figures for Daxor Corporation (as of Nov 6, 2026): return on equity 14.2%, debt of 0.03 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is DXR from its 52-week high?
Daxor Corporation trades at $8.45, about 43% below its 52-week high of $14.75 and at the low of $8.45 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $25.35 is for.
Which stocks are comparable to Daxor Corporation?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daxor Corporation stock attractive at the current price?
The data as of Nov 6, 2026: price $8.45, calculated fair value $25.35 (+200%), Quality Score 57/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DXR calculated?
We run Daxor Corporation through 12 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $25.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daxor Corporation currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daxor Corporation (DXR)?
The closing price on Nov 6, 2026 was $8.45. Our model-based fair value is $25.35, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daxor Corporation right now?
The price is below even our cautious bear case ($18.20). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Daxor Corporation

How large is the market capitalisation of Daxor Corporation (DXR)?
The market capitalisation of Daxor Corporation is $52.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Daxor Corporation (DXR)?
Earnings per share at Daxor Corporation are $1.10 (price ÷ EPS = P/E 7.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Daxor Corporation (DXR)?
The return on equity (ROE) of Daxor Corporation is 14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daxor Corporation (DXR)?
On an EBIT basis the return on assets of Daxor Corporation is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daxor Corporation (DXR)?
The operating margin of Daxor Corporation is −4,530% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daxor Corporation (DXR)?
Revenue at Daxor Corporation is growing +25.5% versus a year earlier (3y avg −57.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daxor Corporation (DXR)?
Earnings per share at Daxor Corporation are growing +329% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daxor Corporation (DXR) generate?
The free cash flow of Daxor Corporation is −$604K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daxor Corporation (DXR) carry?
The net debt of Daxor Corporation is $112K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Daxor Corporation in the live analysis

One click puts Daxor Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.